enVVeno Medical Corp: 10-K/A filed 2025-02-28
What enVVeno Medical Corp reported in its annual report amendment filed 2025-02-28 (fiscal FY 2024): 32 published measures, 64 facts as tagged in accession 0001493152-25-008739.
This is an amendment. Values here are as tagged in the amendment; the original filing has its own page.
This filing
- Form
- 10-K/A (annual report amendment)
- Filed
- 2025-02-28
- Fiscal period
- fiscal FY 2024
- Accession
- 0001493152-25-008739 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All enVVeno Medical Corp filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-12-31 | 44,954,000 | USD | |
| At 2023-12-31 | 48,635,000 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-12-31 | 2,795,000 | USD | |
| At 2023-12-31 | 2,435,000 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-12-31 | 42,159,000 | USD | |
| At 2023-12-31 | 46,200,000 | USD | |
| At 2022-12-31 | 38,729,000 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-12-31 | 1,754,000 | USD | |
| At 2023-12-31 | 3,620,000 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-12-31 | -21,819,000 | USD | 366 |
| 2023-01-01 to 2023-12-31 | -23,516,000 | USD | 365 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-12-31 | -16,838,000 | USD | 366 |
| 2023-01-01 to 2023-12-31 | -18,858,000 | USD | 365 |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-12-31 | 37,000 | USD | 366 |
| 2023-01-01 to 2023-12-31 | 33,000 | USD | 365 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-12-31 | 13,637,000 | USD | 366 |
| 2023-01-01 to 2023-12-31 | 25,791,000 | USD | 365 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-12-31 | 1,335,000 | USD | 366 |
| 2023-01-01 to 2023-12-31 | -7,868,000 | USD | 365 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-12-31 | -151,855,000 | USD | |
| At 2023-12-31 | -130,036,000 | USD |
Basic weighted-average shares
Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-12-31 | 17,142,000 | shares | 366 |
| 2023-01-01 to 2023-12-31 | 12,301,000 | shares | 365 |
Diluted weighted-average shares
Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-12-31 | 17,142,000 | shares | 366 |
| 2023-01-01 to 2023-12-31 | 12,301,000 | shares | 365 |
Basic earnings per share
Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-12-31 | -1.27 | USD/shares | 366 |
| 2023-01-01 to 2023-12-31 | -1.91 | USD/shares | 365 |
Diluted earnings per share
Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-12-31 | -1.27 | USD/shares | 366 |
| 2023-01-01 to 2023-12-31 | -1.91 | USD/shares | 365 |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-12-31 | 182,000 | USD | |
| At 2023-12-31 | 334,000 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-12-31 | 4,141,000 | USD | 366 |
| 2023-01-01 to 2023-12-31 | 5,196,000 | USD | 365 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-12-31 | -23,826,000 | USD | 366 |
| 2023-01-01 to 2023-12-31 | -25,238,000 | USD | 365 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-12-31 | 43,734,000 | USD | |
| At 2023-12-31 | 46,923,000 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-12-31 | 2,095,000 | USD | |
| At 2023-12-31 | 1,371,000 | USD |
Selling, general and administrative expense
Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-12-31 | 11,577,000 | USD | 366 |
| 2023-01-01 to 2023-12-31 | 11,655,000 | USD | 365 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-12-31 | 12,249,000 | USD | 366 |
| 2023-01-01 to 2023-12-31 | 13,583,000 | USD | 365 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-12-31 | 17,536,000 | shares | |
| At 2023-12-31 | 13,317,000 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-12-31 | 194,014,000 | USD | |
| At 2023-12-31 | 176,236,000 | USD |
Operating lease right-of-use asset
Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-12-31 | 1,007,000 | USD | |
| At 2023-12-31 | 1,347,000 | USD |
Operating lease liability
Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-12-31 | 1,064,000 | USD |
Gross property, plant and equipment
Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-12-31 | 1,439,000 | USD | |
| At 2023-12-31 | 1,403,000 | USD |
Accumulated depreciation on property, plant and equipment
Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-12-31 | 1,257,000 | USD | |
| At 2023-12-31 | 1,069,000 | USD |
Prepaid expenses and other current assets
Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-12-31 | 581,000 | USD | |
| At 2023-12-31 | 511,000 | USD |
Net deferred tax assets
Deferred tax assets after the valuation allowance. Realization depends on future taxable income, so the balance is not a receivable from tax authorities.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-12-31 | 30,315,000 | USD | |
| At 2023-12-31 | 24,892,000 | USD |
Depreciation expense
Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-12-31 | 200,000 | USD | 366 |
| 2023-01-01 to 2023-12-31 | 200,000 | USD | 365 |
Nonoperating income or expense
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-12-31 | 2,007,000 | USD | 366 |
| 2023-01-01 to 2023-12-31 | 1,722,000 | USD | 365 |
Operating lease payments
Cash paid for operating lease liabilities during the period. It differs from lease expense recognized and excludes variable payments in some presentations.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-12-31 | 387,000 | USD | 366 |
| 2021-11-16 to 2021-11-17 | 30,206,000 | USD | 2 |
Inspect the source
- Entity
- enVVeno Medical Corp / CIK 0001661053
- Captured
- 2026-09-21T17:22:18.215Z
- SEC response SHA-256
73fd3a753c369da539db4e2bb56f95788b8fd510e4d88840cde32521d8881b95
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001661053.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))